Cash Cash Equivalents - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Epizyme Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Cash & Cash Equivalents
$71.1m
CAGR 3-Years
16%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$13.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$2.8B
CAGR 3-Years
-17%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9.3B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
8%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$4.6B
CAGR 3-Years
-9%
CAGR 5-Years
7%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$1.9B
CAGR 3-Years
-2%
CAGR 5-Years
13%
CAGR 10-Years
12%

See Also

What is Epizyme Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
71.1m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Cash & Cash Equivalents amounts to 71.1m USD.

What is Epizyme Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-4%

Over the last year, the Cash & Cash Equivalents growth was -11%. The average annual Cash & Cash Equivalents growth rates for Epizyme Inc have been 16% over the past three years , -4% over the past five years .

Back to Top